

Author Relationships With Industry and Other Entities (Comprehensive)— 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (March 2015)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Marie D. Gerhard-Herman <i>(Chair)</i>	Harvard Medical School— Associate Professor	None	None	None	• Progeria Research Foundation*	• American Board of Internal Medicine Cardiovascular Exam Committee	None
Heather L. Gornik <i>(Vice Chair)</i>	Cleveland Clinic Foundation, Cardiovascular Medicine— Medical Director, Noninvasive Vascular Laboratory	None	None	• Summit Doppler Systems • Zin Medical	• AstraZeneca • Theravasc	• Fibromuscular Dysplasia Society of America† • IAC Vascular Testing • Intersocietal Commission for the Accreditation of Vascular Laboratories† • PCORI • Society of Vascular Medicine†	None
Coletta Barrett	Our Lady of the Lake Regional Medical Center—Vice President	None	None	None	None	None	None
Neil R. Barshes	Baylor College of Medicine, Division of Vascular Surgery and Endovascular Therapy Michael E. DeBakey Department of Surgery— Assistant Professor	None	None	None	None	None	None
Matthew A. Corriere	University of Michigan— Frankel Professor of Cardiovascular Surgery, Associate Professor of Surgery	None	None	None	None	• Vascular Cures and Society for Vascular Surgery Foundation*	None
Douglas E. Drachman	Massachusetts General Hospital—Training Director	• Abbott Vascular • Corindus Vascular Robotics • St. Jude Medical	None	None	• Atrium Medical • Bard • iDEV Technologies • Lutonix • PLC Medical Systems • Prairie Education and Research Cooperative	None	None
Lee Fleisher	University of Pennsylvania Health System Department of Anesthesiology and Critical Care—Chair	• Blue Cross/Blue Shield Association-Medical Advisory Panel to the Technology Evaluation Center	None	None	• Johns Hopkins Medical Institutions	• Association of University Anesthesiologists† • Foundation for Anesthesia Education and Research†	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		<ul style="list-style-type: none"> • National Quality Forum 					
Francis Gerry R. Fowkes	University of Edinburgh—Emeritus Professor of Epidemiology	<ul style="list-style-type: none"> • AstraZeneca* • Bayer • Merck 	None	None	None	None	None
Naomi M. Hamburg	Boston University School of Medicine, Cardiovascular Medicine Section—Associate Professor of Medicine	<ul style="list-style-type: none"> • Acceleron Pharma* 	None	None	<ul style="list-style-type: none"> • Everest Genomics* • Hershey's* • Unex* • Welch's 	<ul style="list-style-type: none"> • Intersocietal Commission for the Accreditation of Vascular Laboratories‡ 	None
Scott Kinlay	VA Boston Healthcare System—Associate Chief, Cardiology Director, Cardiac Catheterization Laboratory & Vascular Medicine	None	None	None	<ul style="list-style-type: none"> • Medtronic* • The Medicines Company* 	None	None
Robert Lookstein	Mount Sinai Medical Center—Chief, Interventional Radiology; Professor of Radiology and Surgery; Vice Chair, Department of Radiology	<ul style="list-style-type: none"> • Boston Scientific • Medrad Interventional • Possis • The Medicines Company 	<ul style="list-style-type: none"> • Cordis† 	None	<ul style="list-style-type: none"> • Veniti • Shockwave (DSMB) 	None	None
Sanjay Misra	Mayo Clinic, Division of Vascular and Interventional Radiology—Professor; Department of Radiology—Interventional Radiologist	None	None	None	<ul style="list-style-type: none"> • Johnson & Johnson (DSMB) 	None	None
Leila Mureebe	Duke University Medical Center—Associate Professor of Surgery, Division of Vascular Surgery	None	None	None	None	None	None
Jeffrey W. Olin	Ichan School of Medicine at Mount Sinai, Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health—Professor of Medicine, Cardiology; Director, Vascular Medicine	<ul style="list-style-type: none"> • AstraZeneca • Fibromuscular Dysplasia Society of America† • Merck • Novartis • Plurestem 	None	<ul style="list-style-type: none"> • Northwind* 	<ul style="list-style-type: none"> • AstraZeneca* 	None	None
Rajan Patel	John Ochsner Heart & Vascular Center, Ochsner Clinical School, University of Queensland School of Medicine—Senior Lecturer	None	None	None	<ul style="list-style-type: none"> • Aastrom • Abbott • NHLBI 	<ul style="list-style-type: none"> • Abiomed 	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Judith G. Regensteiner	University of Colorado, Health Sciences Center, Division of Cardiology—Associate Professor of Medicine	None	None	None	None	None	None
Andres Schanzer	University of Massachusetts Medical School—Professor of Surgery and Quantitative Health Sciences; Program Director, Vascular Surgery Residency	• Cook Medical	None	None	None	None	None
Mehdi H. Shishehbor	Cleveland Clinic, Interventional Cardiology and Vascular Medicine—Director, Endovascular Services	• Boston Scientific† • Medtronic†	None	None	None	• Astra Zeneca • NIH • Volcano/Philips	None
Kerry J. Stewart	Johns Hopkins University, School of Medicine; Johns Hopkins Bayview Medical Center—Professor of Medicine; Director, Clinical and Research Exercise Physiology	None	None	None	• Society of Women's Health Research*	None	None
Diane Treat-Jacobson	University of Minnesota, School of Nursing—Professor	None	None	None	• NHLBI*	None	None
M. Eileen Walsh	University of Toledo, College of Nursing—Professor	None	None	None	None	• American Nurses Credentialing Center† • Journal of Vascular Nursing (Editorial Board)†	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

DSMB indicates data safety monitoring board; IAC, Intersocietal Accreditation Commission; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institute of Health; and PCORI, Patient-Centered Outcomes Research Institute.